Alpha-7 nicotinic cholinergic receptor (α7 nAChR) (α7 nAChR)

The Alpha-7 nicotinic cholinergic receptor (α7 nAChR) is a homopentameric ligand-gated ion channel primarily expressed in the central nervous system and on immune cells (UniProt P36544). It plays a critical role in modulating synaptic plasticity, neurotransmitter release, and cognitive processes such as attention and memory (PubMed: 28249559). In the brain, α7 nAChRs are highly permeable to calcium, which triggers intracellular signaling pathways involved in neuroprotection and long-term potentiation (StatPearls: NBK542274). Beyond the nervous system, these receptors are key components of the cholinergic anti-inflammatory pathway, where their activation on macrophages inhibits the production of pro-inflammatory cytokines (PubMed: 12447337). Dysregulation of α7 nAChR expression or function is strongly linked to the pathophysiology of schizophrenia and Alzheimer's disease, making it a high-priority target for cognitive enhancers (PubMed: 25637201). Therapeutic strategies include the development of full or partial agonists and positive allosteric modulators (PAMs) to overcome the rapid desensitization characteristic of this receptor (PubChem: SID 472386421). Clinical trials have explored α7 nAChR ligands for treating cognitive impairment associated with schizophrenia (CIAS) and Alzheimer's-related dementia, though many have faced challenges in efficacy (PubMed: 28249559). The receptor's unique ability to signal through both ionotropic and metabotropic-like mechanisms adds complexity to its role in cellular homeostasis and drug response.

Other names

CHRNA7Neuronal acetylcholine receptor subunit alpha-7Alpha7 nicotinic receptorCholinergic receptor nicotinic alpha 7 subunit

Agonism, partial agonism, and positive allosteric modulation (PAM) to enhance cholinergic signaling and modulate neurotransmitter release (PubMed: 25637201).